Compare Cytokinetics Inc (CYTK) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Okta, Inc. — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Okta, Inc. trades at $232.13 (market cap $38.50B). The key difference: Okta, Inc. is far larger — about 4.5× Cytokinetics Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Okta, Inc. for 44 Days on average.
| CYTK | OKTA | |
|---|---|---|
Market Cap | $8.62B | $38.50B |
Volume | 2,594,626 | 2,479,621 |
Sector | Health | Technology |
52-Week High | $87.26 | $220.21 |
52-Week Low | $54.76 | $62.93 |
Typical Hold Time | 19 Days | 44 Days |
Enterprise Value | $8.72B | $36.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
OKTA trades at $220.21, up 1.01% on the day, with a bullish technical signal from moving averages and strong analyst support (73.58% buy ratings). The company reported a net income of $28 million in 2025, marking a return to profitability after losses in prior years, with revenue growing to $2.61 billion. Recent news highlights its AI agent security initiatives, including the Blueprint Alliance unveiled at Oktane 2026.
The outlook is positive due to earnings beats, AI-driven growth potential, and improving cash flow, but risks include high valuation multiples (P/E of 132.66) and competitive pressures in cybersecurity. The stock trades above the consensus price target of $201.30, suggesting near-term consolidation may occur despite long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
